Clene Inc. Advances Neurofilament Biomarker Analysis for CNM-Au8 in ALS with FDA Support
Clene Inc. is set to conduct a neurofilament biomarker analysis for CNM-Au8 in ALS patients, following constructive FDA feedback, aiming to support an accelerated approval submission in 2025.
